CU20160089A7 - PIPERIDINILTETRAHIDROQUINOLINAS SUSTITUIDAS COMO RECEPTORES ADRENÉRGICOS a2C - Google Patents
PIPERIDINILTETRAHIDROQUINOLINAS SUSTITUIDAS COMO RECEPTORES ADRENÉRGICOS a2CInfo
- Publication number
- CU20160089A7 CU20160089A7 CUP2016000089A CU20160089A CU20160089A7 CU 20160089 A7 CU20160089 A7 CU 20160089A7 CU P2016000089 A CUP2016000089 A CU P2016000089A CU 20160089 A CU20160089 A CU 20160089A CU 20160089 A7 CU20160089 A7 CU 20160089A7
- Authority
- CU
- Cuba
- Prior art keywords
- diabetic
- disorders
- peripheral
- prevention
- ulcers
- Prior art date
Links
- 108060003345 Adrenergic Receptor Proteins 0.000 title 1
- 102000017910 Adrenergic receptor Human genes 0.000 title 1
- -1 PIPERIDINYL Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 230000002093 peripheral effect Effects 0.000 abstract 2
- STWMVDMOJPLMPX-UHFFFAOYSA-N 1-piperidin-1-yl-3,4-dihydro-2h-quinoline Chemical class C1CCCCN1N1C2=CC=CC=C2CCC1 STWMVDMOJPLMPX-UHFFFAOYSA-N 0.000 abstract 1
- 206010061666 Autonomic neuropathy Diseases 0.000 abstract 1
- 201000002829 CREST Syndrome Diseases 0.000 abstract 1
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 208000008960 Diabetic foot Diseases 0.000 abstract 1
- 206010056340 Diabetic ulcer Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000009101 diabetic angiopathy Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 208000021156 intermittent vascular claudication Diseases 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003836 peripheral circulation Effects 0.000 abstract 1
- 208000027232 peripheral nervous system disease Diseases 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente solicitud se relaciona con nuevas piperidiniltetrahidroquinolinas sustituidas de fórmula general (I) ESPACIO PARA FÓRMULA con procesos intermedios para su preparacion. Los compuestos de fóruña (I) son útiles para el el tratamiento y/o prevención de enfermedades, en particular para el tratamiento y/o prevención de microangiopatías diabéticas, úlceras diabéticas de las extremidades, en particular para promover el curado de heridas de úlceras de pie diabético, falla cardiaca diabética, trastornos cardiacos microvasculares coronarios diabéticos, trastornos vasculares periféricos y cardiacos, trastornos tromboembolíticos e isquemias, trastornos de la circulación periférica, fenómeno de Raynaud, síndrome de CREST, trastornos microcirculatorios, claudicación intermitente, y neuropatías periféricas y autónomas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13198388 | 2013-12-19 | ||
| EP14192878 | 2014-11-12 | ||
| PCT/EP2014/077865 WO2015091417A1 (de) | 2013-12-19 | 2014-12-16 | Substituierte piperidinyl-tetrahydrochinoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20160089A7 true CU20160089A7 (es) | 2016-10-28 |
Family
ID=52102673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2016000089A CU20160089A7 (es) | 2013-12-19 | 2016-06-16 | PIPERIDINILTETRAHIDROQUINOLINAS SUSTITUIDAS COMO RECEPTORES ADRENÉRGICOS a2C |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9624198B2 (es) |
| EP (1) | EP3083593A1 (es) |
| JP (1) | JP2017501164A (es) |
| KR (1) | KR20160098424A (es) |
| CN (1) | CN105980374A (es) |
| AP (1) | AP2016009303A0 (es) |
| AU (1) | AU2014364735A1 (es) |
| CA (1) | CA2934133A1 (es) |
| CR (1) | CR20160277A (es) |
| CU (1) | CU20160089A7 (es) |
| DO (1) | DOP2016000148A (es) |
| EA (1) | EA201691278A1 (es) |
| IL (1) | IL246271A0 (es) |
| MX (1) | MX2016008114A (es) |
| PE (1) | PE20160842A1 (es) |
| PH (1) | PH12016501146A1 (es) |
| SG (1) | SG11201604949XA (es) |
| TN (1) | TN2016000249A1 (es) |
| WO (1) | WO2015091417A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200052A1 (ar) * | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c |
| WO2018197333A1 (en) | 2017-04-27 | 2018-11-01 | Bayer Aktiengesellschaft | Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
| MX2021005842A (es) * | 2018-11-20 | 2021-07-15 | Bayer Ag | Antagonistas de los adrenoreceptores a2 subtipo c (alfa-2c) para el tratamiento de la apnea del sueño. |
| WO2020165031A1 (de) * | 2019-02-15 | 2020-08-20 | Bayer Aktiengesellschaft | Substituierte isochinolin-piperidinylmethanon-derivate |
| CN113330009B (zh) * | 2019-03-12 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、其制备方法及用途 |
| WO2021126728A1 (en) * | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| CA3222626A1 (en) * | 2021-05-13 | 2022-11-17 | Yunlong Song | Compound having anti-tumor activity and use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69430861T2 (de) | 1993-04-07 | 2003-01-23 | Otsuka Pharmaceutical Co., Ltd. | N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen |
| CA2241567A1 (en) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| RU2215004C2 (ru) | 1997-07-16 | 2003-10-27 | Ново Нордиск А/С | Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| UA69420C2 (uk) | 1998-10-06 | 2004-09-15 | Янссен Фармацевтика Н.В. | ТРИЦИКЛІЧНІ <font face="Symbol">D3</font>-ПІПЕРИДИНИ ЯК <font face="Symbol">a<sub></font>2</sub>-АНТАГОНІСТИ |
| SK286968B6 (sk) | 1999-05-04 | 2009-08-06 | Schering Corporation | Piperidín-piperidinyl ako CCR5 antagonista, farmaceutický prostriedok s jeho obsahom a jeho použitie |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6444681B1 (en) | 2000-06-09 | 2002-09-03 | The Ohio State University Research Foundation | Methods and compositions for treating Raynaud's Phenomenon and scleroderma |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| GB0108876D0 (en) | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
| AR036366A1 (es) * | 2001-08-29 | 2004-09-01 | Schering Corp | Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| WO2004067513A1 (en) | 2003-01-27 | 2004-08-12 | Oy Juvantia Pharma Ltd | Antagonists for alpha-2 adrenoceptors |
| JP4757802B2 (ja) | 2003-11-03 | 2011-08-24 | シェーリング コーポレイション | ケモカインレセプターの阻害剤として有用なビピペリジニル誘導体 |
| ES2324224T3 (es) | 2004-02-05 | 2009-08-03 | Schering Corporation | Derivados de piperidina que se pueden utilizar como antagonistas ccr3. |
| CN101189012A (zh) | 2005-03-31 | 2008-05-28 | 詹森药业有限公司 | 苯基和吡啶基lta4h调节剂 |
| TW201024282A (en) | 2008-11-20 | 2010-07-01 | Orion Corp | New pharmaceutical compounds |
| CA2830882C (en) | 2011-03-22 | 2021-03-16 | Dinesh Barawkar | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
-
2014
- 2014-12-16 JP JP2016540498A patent/JP2017501164A/ja active Pending
- 2014-12-16 CA CA2934133A patent/CA2934133A1/en not_active Abandoned
- 2014-12-16 EA EA201691278A patent/EA201691278A1/ru unknown
- 2014-12-16 CR CR20160277A patent/CR20160277A/es unknown
- 2014-12-16 MX MX2016008114A patent/MX2016008114A/es unknown
- 2014-12-16 EP EP14812505.7A patent/EP3083593A1/de not_active Withdrawn
- 2014-12-16 PE PE2016000841A patent/PE20160842A1/es not_active Application Discontinuation
- 2014-12-16 TN TN2016000249A patent/TN2016000249A1/en unknown
- 2014-12-16 SG SG11201604949XA patent/SG11201604949XA/en unknown
- 2014-12-16 AP AP2016009303A patent/AP2016009303A0/en unknown
- 2014-12-16 US US15/106,283 patent/US9624198B2/en not_active Expired - Fee Related
- 2014-12-16 KR KR1020167018959A patent/KR20160098424A/ko not_active Withdrawn
- 2014-12-16 AU AU2014364735A patent/AU2014364735A1/en not_active Abandoned
- 2014-12-16 WO PCT/EP2014/077865 patent/WO2015091417A1/de not_active Ceased
- 2014-12-16 CN CN201480075854.4A patent/CN105980374A/zh active Pending
-
2016
- 2016-06-14 PH PH12016501146A patent/PH12016501146A1/en unknown
- 2016-06-16 CU CUP2016000089A patent/CU20160089A7/es unknown
- 2016-06-16 IL IL246271A patent/IL246271A0/en unknown
- 2016-06-17 DO DO2016000148A patent/DOP2016000148A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017501164A (ja) | 2017-01-12 |
| US20160304491A1 (en) | 2016-10-20 |
| EA201691278A1 (ru) | 2017-02-28 |
| AU2014364735A1 (en) | 2016-07-07 |
| KR20160098424A (ko) | 2016-08-18 |
| SG11201604949XA (en) | 2016-07-28 |
| US9624198B2 (en) | 2017-04-18 |
| WO2015091417A8 (de) | 2016-08-11 |
| PH12016501146A1 (en) | 2016-08-15 |
| PE20160842A1 (es) | 2016-09-24 |
| IL246271A0 (en) | 2016-08-02 |
| MX2016008114A (es) | 2017-01-20 |
| AP2016009303A0 (en) | 2016-06-30 |
| CA2934133A1 (en) | 2015-06-25 |
| TN2016000249A1 (en) | 2017-10-06 |
| DOP2016000148A (es) | 2016-07-15 |
| EP3083593A1 (de) | 2016-10-26 |
| CR20160277A (es) | 2016-10-14 |
| WO2015091417A1 (de) | 2015-06-25 |
| CN105980374A (zh) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20160089A7 (es) | PIPERIDINILTETRAHIDROQUINOLINAS SUSTITUIDAS COMO RECEPTORES ADRENÉRGICOS a2C | |
| NI201600084A (es) | Piperidinil tetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c. | |
| UY31616A1 (es) | Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica | |
| CO7240369A2 (es) | Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso | |
| EA201500996A1 (ru) | Терапевтические применения эмпаглифлозина | |
| MX2020001835A (es) | Métodos para el tratamiento de retinopatía diabética y otras enfermedades oftálmicas. | |
| DOP2012000246A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| BR112017010592A2 (pt) | análogos de ureia ligados em ponte substituídos como moduladores de sirtuína | |
| ECSP099518A (es) | Uso de derivados de ácido de piranona sustituidos para el tratamiento del síndrome metabólico | |
| ITMI20120370A1 (it) | Miscela antimicrobica e rivestimento per supportare la guarigione di ferite, che ha un effetto antimicrobico. | |
| CU20090216A7 (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea | |
| MX2020007462A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| GT201300125A (es) | 1h-pirazol-5-olato sódico sustituido | |
| MX2023012851A (es) | Métodos de tratamiento y seguimiento de la enfermedad de parkinson. | |
| DOP2010000156A (es) | Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca | |
| CL2013000021A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable. | |
| CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. | |
| SE0401943D0 (sv) | New use | |
| CR20150641U (es) | Composiciones farmacéuticas | |
| CY1119117T1 (el) | Δερμοπροστατευτικη και δερμο-εξισορροπητικη συνθεση | |
| AR118705A2 (es) | Polipéptido del factor vii para tratar enfermedades, método para prepararlo y composición que lo contiene | |
| AR098788A1 (es) | Piperidinil-tetrahidroquinolinas sustituidas |